DRUG SPECIAL AUTHORIZATION REQUEST FORM, PREFERRED PHARMACY NETWORK, AND ADHERENCE SUPPORT PROGRAM INFORMATION

COMPLETING YOUR FORM…

To ensure prompt processing of your request, please complete the following Special Authorization Request Form in full. Note that there are sections that must be completed by you, the patient, and sections that must be completed by **your prescriber**. Once completed, submit the form to Green Shield Canada (GSC) via your method of choice:

By email: drugspecial.autho@greenshield.ca

By fax: 1.866.797.6483

By mail: Green Shield Canada, Drug Special Authorization Department
P.O. Box 1606, Windsor ON N9A 6W1

Note that submission of an incomplete form may result in delays.

Your request will be reviewed and evaluated by our Drug Special Authorization Department who will share the results with you. Should you have any questions, call GSC's Contact Centre at 1.888.711.1119.

OTHER DRUG COVERAGE...

If you are eligible for coverage by another plan (public or private), indicate that in Section 1B of the authorization form.

If you have provincial drug coverage, please ensure that your prescriber has applied for coverage under your primary provincial drug plan. The result of that application must be attached to the completed Special Authorization Request Form.

PREFERRED PHARMACY NETWORK (PPN)

If your request for coverage is approved, you may be required to obtain your special authorization drug at an approved pharmacy. If this applies to your benefits plan, a care coordinator working on behalf of GSC will contact you to help you find an approved pharmacy near you. The care coordinator will also work with you and your physician to arrange to have your prescription sent to the pharmacy you select.

Should you choose not to speak with the care coordinator, and you obtain your special authorization drug at an unapproved pharmacy, your claim may not be paid under your benefits plan.

ADHERENCE SUPPORT PROGRAM

Some drug treatment plans are complicated, and patients can sometimes find it difficult to follow their prescriber's instructions when taking their medication. If your special authorization drug is approved, you may be eligible for adherence support services. A medication management specialist can work with you to ensure that you have the support necessary to take your medication as instructed and adhere to your drug treatment plan.

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM

Please note: Incomplete information may delay your request for processing.

SECTION 1A – PATIENT INFORMATION

First Name		Green Shield ID	Employer Name
Last Name		Date of Birth (YYYY/MM/DD)	Email Address
Street Address			Telephone (Home)
City	Province	Postal Code	Telephone (Mobile)

SECTION 1B - COORDINATION OF BENEFITS

Patient Support Program

Is the patient enrolled in any assistance program for the requested drug? ☐ Yes ☐ No

Program Name			Patient Identifier
Contact First Name	Contact Last Name	Contact Phone	Contact Email

Drug Access Navigator

Is the patient in contact with an alternate drug access navigator (i.e., hospital)? ☐ Yes ☐ No

Organization Name			
Contact First Name	Contact Last Name	Contact Phone	Contact Email

Provincial Coverage

Has the patient applied for reimbursement under a provincial plan? ☐ Yes ☐ No ☐ NA

What is the coverage decision? (Attach decision outcome letter) ☐ Approved ☐ Denied

Other Private Coverage

Is this patient covered by any other plan? (If yes answer below) ☐ Yes ☐ No ☐ NA

Planholder First Name	Planholder Last Name	Date of Birth (YYYY/MM/DD)

Relationship to Planholder ☐ Self ☐ Spouse ☐ Dependant ☐ Other _____

What is the coverage decision? (Attach outcome letter if received) ☐ Approved ☐ Denied

SECTION 1C – CONSENT

I hereby authorize any licensed physician/dentist, medical practitioner, hospital, patient assistance program, clinic, or medically related facility to provide to Green Shield Canada information regarding my health as it relates to this request. I hereby authorize Green Shield Canada to obtain and exchange personal information with other parties as required, including any health care provider, patient assistance program and/or preferred pharmacy network (PPN) vendor working with Green Shield Canada for the purpose of administering this benefit. I acknowledge that my personal information is needed to assess eligibility for this drug, to administer the group benefits plan, and where applicable, to administer pharmacy preferred provider network and patient support programs on my behalf. I acknowledge that my personal information may be exchanged and transferred between these parties for these purposes and may include information about my drug claims, diagnosis, medical condition, treatment, and other health related information. I acknowledge that providing my consent will help Green Shield Canada to assess my claim and that refusing to consent may result in delay or denial of my claim. This consent may be revoked by me at any time by sending written instructions to that effect at the address indicated below.

I understand that personal information may be subject to disclosure to those authorized under applicable law within Canada only when the information is needed to administer this benefit and/or to confirm the accuracy of this information. I certify that the information given is true, correct, and complete to the best of my knowledge.

Signature of Patient	**Date (YYYY/MM/DD)**

If under 16 years of age (14 years of age in Quebec), the signature of the parent / guardian is required.

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM
PCSK9 INHIBITORS AND ANTILIPEMIC siRNA AGENT

SECTION 2A – DRUG REQUESTED FOR EVALUATION

Product Name and Strength	
Dose	Frequency of Administration
Route (ex. oral, IV, etc.)	Therapy Duration

Is the patient currently on the requested therapy? (If yes provide therapy start date) ☐ Yes ☐ No Therapy Start Date (YMD) _____

If already established on therapy, please attach proof of payment and details of prior coverage. Individuals established on therapy through compassionate coverage will only be considered if they met GSC criteria on initiation of therapy.

SECTION 2B – LOCATION OF ADMINISTRATION

☐ Home
☐ Physician's Office
☐ Hospital (In-Patient)
☐ Hospital (Out-Patient)
☐ Infusion Center

For Infusion Centers please complete information below

Name and Address of Infusion Center		
City	Province	Postal Code

SECTION 2C – DRUG REQUESTED FOR EVALUATION

Please check off the box next to the drug you are requesting for evaluation:

☐ Praluent® (alirocumab) ☐ Repatha® (evolocumab) ☐ Leqvio™ (inclisiran)

SECTION 2D – CLINICAL INFORMATION

Please specify the diagnosis:

☐ Homozygous Familial Hypercholesterolemia (HoFH)

☐ Heterozygous Familial Hypercholesterolemia (HeFH)

Please specify the diagnostic tool used:
☐ Simon Broome
☐ Dutch Lipid
☐ Other: _____

Please specify the result:
☐ Definite
☐ Probable
☐ Possible
☐ Other: _____

☐ Atherosclerotic Cardiovascular Disease (ASCVD)

Please specify the etiology:
☐ Myocardial Infarction (MI)
☐ Stable or Unstable Angina
☐ Coronary Artery Disease (CAD)

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM
PCSK9 INHIBITORS AND ANTILIPEMIC siRNA AGENT

☐ Stroke, Transient Ischemic Attack (TIA) or Carotid Disease
☐ Peripheral Artery Disease (PAD)
☐ Abdominal Aortic Aneurysm
☐ Other: _____

Cholesterol bloodwork report MUST be submitted for review that meets the following criteria:

- From the previous six months
- Preceded by at least four months of consistent statin and ezetimibe use, if applicable
- Adherence to statins or other lipid-lowering agents will be verified with claims data.

Most recent LDL-C level: _____

If triglyceride levels is > 1.5 mmol/L, provide the most recent non-HDL-C or apoB level: _____

Date: _____

LDL-C, non-HDL-C and apoB values will be assessed with respect to the targets outlined by the Canadian Cardiovascular Society in the following guidelines:

- *Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018*
- *2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults*

Please provide further details on the medication history for lipid-lowering therapies:

Will the PCSK9 inhibitor or antilipemic siRNA agent be used with other lipid-lowering therapies?
☐ Yes ☐ No

Statin Trial History:

Patient must have trialed at least one high-intensity statin at the maximum tolerated dose and ezetimibe.
High-intensity statins include atorvastatin ≥ 40mg or rosuvastatin ≥ 20mg.

Regimen #1:
Name: _____
Dose: _____
Start Date: _____
Stop Date: _____

If stopped, please describe rationale for discontinuation:

- ☐ Allergic reaction
- ☐ Myalgias
- ☐ Hepatoxicity (please provide Liver Function Tests for documentation)
- ☐ Rhabdomyolysis (please provide Creatine Kinase labs for documentation)
- ☐ Other (with supporting documentation, if applicable): _____

Regimen #2:

Name: _____

Dose: _____

Start Date: _____

Stop Date: _____

If stopped, please describe rationale for discontinuation:

- ☐ Allergic reaction
- ☐ Myalgias
- ☐ Hepatoxicity (please provide Liver Function Tests for documentation)
- ☐ Rhabdomyolysis (please provide Creatine Kinase labs for documentation)
- ☐ Other (with supporting documentation, if applicable): _____

Ezetimibe Trial History:

Start Date: _____

Stop Date: _____

If stopped, please describe rationale for discontinuation:

- ☐ Allergic reaction
- ☐ Intolerance: _____
- ☐ Other (with supporting documentation, if applicable): _____

Other Therapies:

Name: _____

Dose: _____

Start Date: _____

Stop Date: _____

If stopped, please describe rationale for discontinuation:

- ☐ Allergic reaction
- ☐ Intolerance: _____
- ☐ Other (with supporting documentation, if applicable): _____

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM

Please note: Incomplete information may delay your request for processing.

SECTION 3A – PRESCRIBER INFORMATION AND SIGNATURE		
First Name	License Number	Specialty
Last Name	Telephone	Fax
Street Address		
City / Province		Postal Code
Signature		**Date (YYYY/MM/DD)**

SECTION 3B – SUBMISSION INSTRUCTIONS	
Return request form along with any original paid "Official Pharmacy" receipts to :	
Fax : 1.519.739.6483 or 1.866.797.6483 **Email** : drugspecial.autho@greenshield.ca	**Mail**: Green Shield Canada Drug Special Authorization Department, P.O. Box 1606, Windsor ON N9A 6W1

COST OF OBTAINING THIS INFORMATION IS AT THE EXPENSE OF THE PATIENT/PLAN MEMBER.